Symptom Management in Palliative Care

Quick Answer

Palliative care symptom management requires a systematic approach to physical, psychological, and spiritual distress. Pain follows the WHO Analgesic Ladder: Step 1 (non-opioids), Step 2 (weak opioids), Step 3 (strong opioids, morphine first-line). For refractory pain, consider opioid rotation (25-50% dose reduction due to incomplete cross-tolerance) or methadone (NMDA antagonist for neuropathic pain). Dyspnea is managed with low-dose systemic opioids (morphine 2.5-5 mg oral), not benzodiazepines (no evidence for dyspnea) unless significant anxiety present. Oxygen only benefits hypoxemic patients; for non-hypoxemic dyspnea, use fan therapy. Nausea/vomiting: metoclopramide for gastroparesis, haloperidol for metabolic causes, ondansetron for CINV, dexamethasone for malignant bowel obstruction or raised ICP. Delirium: haloperidol no longer first-line for mild-moderate delirium (Agar JAMA 2017: worse outcomes than placebo); focus on non-pharmacological measures, reserve antipsychotics for severe agitation. Terminal restlessness: midazolam continuous infusion (10-20 mg/24h SC) is first-line. Death rattle: prophylactic hyoscine butylbromide 20 mg QID reduces incidence (SILENCE trial). Opioid-induced constipation: proactive laxatives (senna + docusate); if refractory, use methylnaltrexone (PAMORA) subcutaneously. Depression: methylphenidate for rapid relief (24-48h) with short prognosis, mirtazapine for insomnia/anorexia with longer prognosis. Non-pharmacological: music therapy, massage, acupuncture, aromatherapy, dignity therapy.

---

CICM Exam Focus

Written Exam High-Yield Topics:

• WHO Analgesic Ladder: Stepwise approach to pain management
• Opioid rotation: Indications, dose calculations, cross-tolerance principles
• Methadone in palliative care: NMDA antagonism, QTc prolongation, conversion ratios
• Dyspnea management: Opioids vs benzodiazepines vs oxygen evidence
• Nausea/vomiting: Mechanism-based prescribing (gastric stasis, chemical, raised ICP)
• Delirium in palliative care: Agar trial findings, non-pharmacological approaches
• Terminal restlessness: Midazolam dosing, palliative sedation principles
• Death rattle: SILENCE trial, prophylactic vs reactive treatment
• Opioid-induced constipation: Methylnaltrexone mechanism and use
• Non-pharmacological interventions: Evidence for complementary therapies

Viva Voce Themes:

• Pain management: Choosing appropriate step, breakthrough dosing, opioid rotation calculations
• Dyspnea assessment: Differentiating hypoxemic vs non-hypoxemic, role of fan therapy
• Delirium differential: Reversible causes (PINCH ME), when to use antipsychotics
• Palliative sedation: Indications, ethical principles, drug selection
• Family communication: Explaining death rattle, constipation, and anxiety management

---

Key Points

• WHO Analgesic Ladder: Three-step approach (non-opioids → weak opioids → strong opioids) with morphine as gold standard for severe pain
• Opioid rotation: Switch opioids for poor analgesia or intolerable side effects; reduce calculated dose by 25-50% due to incomplete cross-tolerance
• Methadone: Unique NMDA receptor antagonist effective for neuropathic pain; long half-life (8-120 hours) requires dosing changes every 5-7 days; QTc prolongation risk requires ECG monitoring
• Dyspnea opioids: Low-dose morphine (2.5-5 mg oral/SC) significantly reduces breathlessness sensation; safe when titrated carefully
• Benzodiazepines for dyspnea: No evidence of benefit for breathlessness itself (Simon Cochrane 2016); only for associated anxiety or terminal phase sedation
• Oxygen: Only effective for hypoxemic patients (SpO2 below 90-92%); fan therapy more effective for non-hypoxemic dyspnea
• Nausea/vomiting: Metoclopramide for gastric stasis, haloperidol for chemical/metabolic causes, ondansetron for CINV, dexamethasone for MBO/raised ICP
• Delirium: Haloperidol associated with increased symptoms and mortality vs placebo (Agar JAMA 2017); non-pharmacological measures first-line
• Terminal restlessness: Midazolam continuous infusion (10-20 mg/24h SC) is gold standard; add levomepromazine if refractory
• Death rattle: Prophylactic hyoscine butylbromide 20 mg QID reduces incidence from 27% to 13% (SILENCE trial 2021)
• Opioid-induced constipation: Start bowel regimen with opioid initiation; methylnaltrexone (PAMORA) for refractory cases
• Depression: Methylphenidate for rapid relief (24-48h) in short prognosis; mirtazapine for insomnia/anorexia with longer prognosis
• Non-pharmacological: Music therapy, massage, acupuncture, aromatherapy show benefit for anxiety, pain, and nausea

---

Clinical Overview

Pain Management

WHO Analgesic Ladder

The WHO Analgesic Ladder, introduced in 1986 and updated in 2018, provides the foundational framework for cancer pain management. The ladder emphasizes "by the clock, by the mouth, by the ladder"

• medications given regularly, orally when possible, and escalated according to pain intensity.

Step 1: Mild Pain (NRS 1-3)

• Non-opioid analgesics: Acetaminophen (paracetamol) or NSAIDs (ibuprofen, naproxen)
• Adjuvant medications added as needed (corticosteroids, anticonvulsants)

Step 2: Moderate Pain (NRS 4-6)

• "Weak" opioids: Codeine, tramadol, dihydrocodeine
• Usually combined with Step 1 non-opioids
• Modern practice often "skips" Step 2, moving directly to low-dose strong opioids for moderate-severe pain

Step 3: Severe Pain (NRS 7-10)

• Strong opioids: Morphine, oxycodone, hydromorphone, fentanyl, methadone
• Morphine remains gold standard due to extensive clinical experience, availability, and cost-effectiveness
• No ceiling dose; titrated until pain relief or intolerable side effects

Step 4: Interventional (Modern addition)

• Nerve blocks, epidural analgesia, intrathecal pumps, neurolytic procedures for refractory pain

Morphine Dosing and Titration

Morphine remains the reference opioid for palliative care:

Immediate-Release (IR) Morphine for Titration:

• Starting dose: 2.5-5 mg PO q4h PRN (opioid-naïve)
• Titrate every 24 hours based on total rescue doses used
• Calculate total 24-hour dose (scheduled + rescue), increase by 30-50%

Extended-Release (ER) Morphine for Maintenance:

• Convert to ER formulation once effective dose determined
• Same total daily dose divided q12h (MS Contin) or q24h (Kadian)

Breakthrough Pain:

• Provide rescue dose: 10-15% of total 24-hour dose
• Allow up to 6 rescue doses per day; if exceeded, increase scheduled dose

Side Effect Management:

• Constipation: Prophylactic stimulant laxatives (senna) + stool softener (docusate) with all opioid prescriptions
• Nausea: Antiemetic if persistent (haloperidol 0.5-1 mg PO/SC)
• Drowsiness: Usually resolves within 3-5 days; consider dose reduction if problematic

Opioid Rotation

Opioid rotation is switching from one Step 3 opioid to another to improve analgesia or reduce side effects.

Indications for Rotation:

• Poor analgesia despite adequate dose escalation
• Intolerable side effects before effective analgesia achieved:
  • Hallucinations, myoclonus, hyperalgesia (opioid-induced neurotoxicity)
  • Severe sedation
  • Nausea/vomiting refractory to antiemetics
• Inadequate pain relief with acceptable side effects (suggests incomplete cross-tolerance)

Rotation Process:

1. Calculate total 24-hour current opioid dose
2. Convert to Morphine Milligram Equivalents (MME) using conversion table
3. Reduce new opioid dose by 25-50% (incomplete cross-tolerance)
4. Calculate breakthrough dose (10-15% of new scheduled dose)
5. Titrate based on response over 3-5 days

Common Conversion Ratios (to morphine oral):

• Oxycodone PO: 1.5-2x more potent
• Hydromorphone PO: 5-7.5x more potent
• Fentanyl transdermal: Variable (100 mcg/h ≈ morphine PO 60-135 mg/day)
• Methadone: Highly variable (4:1 to 20:1 depending on dose)

Exam Detail: Methadone Conversion Nuances:

• Ratio increases with higher morphine equivalent doses
• below 30 mg morphine/day: ~4:1 ratio
• 30-100 mg morphine/day: ~8:1 ratio
• 100-300 mg morphine/day: ~10:1 ratio
• greater than 300 mg morphine/day: ~12:1 to 20:1 ratio
• Always use published conversion tables; never rely on single ratio

Rotation to Methadone:

• Start low, go slow due to unpredictable half-life
• Dosing changes only every 5-7 days (allow steady-state)
• Baseline ECG required (QTc greater than 450 ms: avoid methadone)
• Repeat ECG when dose greater than 100 mg/day
• Magnesium 2g IV for Torsades if occurs

Methadone in Palliative Care

Methadone has unique properties making it valuable in palliative care:

Dual Mechanism of Action:

• μ-opioid receptor agonist (analgesia)
• NMDA receptor antagonist (prevents wind-up phenomenon)
• Serotonin and norepinephrine reuptake inhibition (additional analgesia)

Indications:

• Neuropathic pain (NMDA antagonism beneficial)
• Opioid-induced hyperalgesia or neurotoxicity
• Renal failure (hepatic metabolism, no active metabolites)
• Patients with high opioid tolerance requiring rotation

Pharmacokinetic Challenges:

• Variable half-life: 8-120 hours (accumulation risk)
• Non-linear kinetics: Higher doses disproportionate prolong half-life
• QTc prolongation: hERG potassium channel blockade
  • "Baseline ECG: Corrected QT interval"
  • "Risk factors: High dose (greater than 100 mg/day), electrolyte abnormalities, concomitant QT-prolonging drugs"
  • "Monitor: Repeat ECG at dose milestones"

Dosing:

• Starting dose: 2.5-5 mg PO q8-12h (opioid-naïve)
• Titrate every 5-7 days (allows steady-state)
• Breakthrough: 5-10% of total daily dose q4h PRN
• Maximum dose: Limited by side effects, not ceiling effect

Monitoring Requirements:

• ECG at baseline, when dose greater than 100 mg/day, and with dose increases
• Electrolytes: Maintain K+ 4.0-4.5 mmol/L, Mg2+ greater than 2.0 mg/dL
• Sedation: May be prominent initially, often improves

---

Dyspnea Management

Dyspnea (breathlessness) affects 50-70% of palliative care patients, with prevalence increasing as disease progresses.

Systemic Opioids (First-Line Pharmacotherapy)

Evidence: Cochrane reviews and meta-analyses confirm low-dose systemic opioids significantly reduce breathlessness sensation in advanced disease.

Mechanism of Action:

• Reduces central perception of dyspnea
• Decreases ventilatory response to hypercapnia and hypoxia
• Reduces anxiety associated with breathlessness

Dosing:

• Morphine oral: 2.5-5 mg q4h PRN (opioid-naïve)
• Morphine SC: 2.5-5 mg q4h PRN
• Titrate to effect; typical effective dose: 10-20 mg/day
• Monitor respiratory rate; ensure patient not overly sedated

Safety:

• When titrated carefully, low-dose opioids do NOT cause clinically significant respiratory depression in palliative populations
• Does NOT shorten life expectancy
• Nebulized opioids: No evidence of benefit over nebulized saline; not recommended

Contraindications/Caution:

• Severe respiratory failure (respiratory rate below 8/min)
• Uncontrolled hypercapnia (CO2 retention)
• Severe COPD with CO2 retention (use extreme caution)

Benzodiazepines (Second/Third-Line)

Evidence: Cochrane review (Simon et al. 2016, PMID 27760456) found no evidence that benzodiazepines relieve breathlessness itself.

Role in Therapy:

• Beneficial for patients with significant co-existing anxiety
• Used in terminal phase for "total distress" management
• Not recommended as monotherapy for dyspnea

Dosing (for anxiety component):

• Lorazepam: 0.5-1 mg PO/SL q6h PRN
• Midazolam: 2.5-5 mg SC q1-2h PRN (terminal phase)
• Diazepam: 2-5 mg PO q6-8h PRN

Side Effects:

• Sedation (may worsen delirium)
• Falls (elderly)
• Paradoxical agitation (small percentage)
• Respiratory depression (when combined with opioids)

Oxygen Management

Evidence: Cochrane review (Ekström et al. 2020) found no significant difference between supplemental oxygen and medical air for non-hypoxemic patients.

Patient Selection:

• Hypoxemic patients (SpO2 below 90-92%): Oxygen effective at reducing dyspnea
• Non-hypoxemic patients: No benefit from oxygen; use fan therapy instead

Oxygen Delivery:

• Nasal cannula: 1-4 L/min (for mild hypoxemia)
• Venturi mask: Precise FiO2 delivery (24%, 28%, 31%, 35%)
• Non-rebreather mask: 15 L/min (severe hypoxemia, carbon monoxide poisoning)

Goal:

• Target SpO2 92-96% (higher targets not proven beneficial)
• Avoid hypoxemia (SpO2 below 88%) while minimizing oxygen toxicity
• Humidified oxygen for comfort if prolonged use

Non-Pharmacological Interventions

Fan Therapy:

• Moving cool air directed at face (hand-held fan or fan)
• Mechanism: Stimulates trigeminal nerve receptors, reduces dyspnea sensation
• Evidence: As effective or more effective than oxygen for non-hypoxemic patients
• Advantages: No side effects, low cost, immediate relief

Positioning:

• Upright sitting (45-90°) reduces diaphragmatic work
• Forward-leaning position (tripod) further improves dyspnea in COPD
• High Fowler's position in bed patients

Breathing Techniques:

• Pursed-lip breathing: Creates back-pressure, prevents airway collapse
• Diaphragmatic breathing: Reduces accessory muscle use
• Coordinated breathing with activities: Prevents breath-holding

Environmental Measures:

• Cool air: Open windows, air conditioning
• Reduce humidity: Dehumidifier for humid climates
• Eliminate triggers: Smoke, aerosols, strong odors

---

Nausea and Vomiting Management

Nausea and vomiting affect 40-70% of advanced cancer patients. Management follows a mechanism-based approach.

Mechanism-Based Prescribing

1. Gastric Stasis / Early Satiety

• First-line: Metoclopramide
  • D2 antagonist + prokinetic
  • "Dose: 10-20 mg PO/SC q6-8h PRN (max 60 mg/day)"
  • "Contra: Bowel obstruction, complete mechanical obstruction"
  • "Side effects: Extrapyramidal symptoms (tremor, dystonia)"

2. Chemical / Metabolic Causes

• Uremia, hypercalcemia, liver failure, opioid-induced
• First-line: Haloperidol
  • "Dose: 0.5-2 mg PO/SC q6-8h PRN (max 10 mg/day)"
  • "Contra: Parkinson's disease (worsens symptoms)"
  • "Side effects: EPS, sedation, QTc prolongation"

3. Raised Intracranial Pressure

• Brain metastases, meningitis, intracranial hemorrhage
• First-line: Dexamethasone
  • "Dose: 4-16 mg PO/IV daily (taper once symptoms controlled)"
  • "Onset: Rapid (within hours)"
  • "Side effects: Hyperglycemia, insomnia, myopathy"

4. Chemotherapy-Induced Nausea and Vomiting (CINV)

• First-line: 5-HT3 antagonists
  • "Ondansetron: 8 mg PO q8h PRN (max 32 mg/day)"
  • "Granisetron: 1-2 mg PO daily"
  • "Palonosetron: 0.5 mg IV single dose (long-acting)"
  • "Note: For general palliative nausea (not chemo-related), ondansetron NOT superior to metoclopramide or placebo"

5. Malignant Bowel Obstruction (MBO)

• First-line: Dexamethasone
  • Reduces peri-tumor edema, may partially relieve obstruction
  • "Dose: 6-16 mg PO/SC daily"
  • "Side effects: Long-term use causes myopathy, hyperglycemia"
• Second-line: Levomepromazine (Methotrimeprazine)
  • Broad-spectrum antiemetic (D2, H1, 5-HT2, ACh receptors)
  • "Dose: 6.25-12.5 mg PO/SC q12-24h"
  • "Highly sedating: Consider alternative if alertness desired"
  • "Note: Not available in all countries (available in UK, Canada, Europe)"

6. Refractory / Multi-factorial Nausea

• Levomepromazine: First choice in UK/Canada
• Olanzapine: Atypical antipsychetic with antiemetic properties
  • "Dose: 2.5-5 mg PO q24h"
  • Emerging evidence for refractory nausea
  • "Side effects: Weight gain, metabolic syndrome"

Exam Detail: 5-HT3 Antagonists Limitations in General Palliative Care:

• JCO study found ondansetron NOT superior to metoclopramide for advanced cancer nausea
• Significant side effect: Constipation (problematic with opioid use)
• High cost compared to haloperidol/metoclopramide
• Reserve for: CINV, post-operative, radiation-induced nausea

Dexamethasone Evidence:

• Strong evidence for MBO and raised ICP
• Large RCT (Acheson study) showed no benefit over placebo for general cancer nausea
• Use when specific indication present

---

Delirium Management

Delirium affects up to 88% of palliative care patients in final days of life. Agar et al. JAMA Internal Medicine 2017 (PMID 27918549) fundamentally changed practice.

Types of Delirium

Hypoactive Delirium (50-75% of cases)

• Quiet, withdrawn, reduced responsiveness
• Often under-recognized compared to hyperactive type
• Antipsychotics NOT indicated (worsens sedation)

Hyperactive Delirium (25-50% of cases)

• Agitated, restless, picking at bedclothes
• Delusions, hallucinations
• Safety risk to patient and others
• Consider antipsychotics for severe agitation only

Mixed Delirium (fluctuating between types)

Reversible Causes (PINCH ME)

Always assess and treat reversible causes before antipsychotics:

• Pain (uncontrolled)
• Infection (UTI, pneumonia, sepsis)
• Nutrition (dehydration, electrolyte abnormalities)
• Constipation (fecal impaction)
• Hydration (dehydration, hypercalcemia)
• Medications (opioid toxicity, benzodiazepine withdrawal, anticholinergics)
• Environmental (restraints, isolation, lack of orientation cues)

Pharmacological Management

Historical Practice (Before 2017):

• Haloperidol first-line for all delirium types
• Risperidone alternative
• Benzodiazepines for terminal agitation

Current Evidence-Based Practice:

Cochrane Review 2020 (Candy et al., PMID 32227341):

• No high-quality evidence for antipsychotics in palliative delirium
• Antipsychotics did not reduce delirium symptoms vs placebo
• Associated with more adverse effects (extrapyramidal symptoms)

Agar RCT 2017 (JAMA Internal Medicine, PMID 27918549):

• 247 participants randomized to haloperidol, risperidone, or placebo
• Haloperidol: Higher delirium symptom scores vs placebo (worse)
• Haloperidol: Higher mortality vs placebo (hazard ratio 1.73)
• Conclusion: Antipsychotics worsened outcomes

Current Recommendations:

1. Non-pharmacological first (for all delirium types)
2. Avoid haloperidol for hypoactive or mild-moderate hyperactive delirium
3. Reserve antipsychotics for:
   • Severe agitation with safety risks
   • Patient distress despite non-pharmacological measures
   • Terminal phase when sedation is goal

When Antipsychotics Indicated (Severe Agitation):

• Haloperidol: 0.5-2 mg PO/SC q6-8h PRN
• Lowest effective dose, shortest duration
• Monitor for EPS
• Consider atypical (quetiapine, olanzapine) if EPS problematic

Non-Pharmacological Management (First-Line)

Environmental Measures:

• Familiar objects, photos, orientation aids (clocks, calendars)
• Consistent caregivers and location
• Adequate lighting (day/night cycle)
• Reduce noise and stimulation at night
• Family presence (reorientation, reassurance)

Communication:

• Simple, clear, repeated explanations
• Reorient frequently to person, place, time
• Validate hallucinations without reinforcing
• Avoid arguing about delusional content

Mobilization:

• Assist with positioning changes
• Encourage ambulation if possible
• Prevent pressure injuries and contractures

Family Education:

• Explain that delirium is common and usually not distressing to patient (if hypoactive)
• Teach gentle reorientation techniques
• Encourage presence and touch

---

Agitation and Terminal Restlessness

Terminal restlessness affects 25-50% of patients in final days of life.

Assessment

Distinguish from Delirium:

• Terminal restlessness is often terminal delirium manifestation
• Agitation without cognitive fluctuation may be anxiety or pain

Assess Reversible Causes (PINCH ME)

• Pain: Assess analgesia adequacy
• Bladder: Urinary retention
• Bowel: Constipation or obstruction
• Environment: Fear, unresolved issues, family distress

Pharmacological Management

Midazolam (First-Line for Terminal Restlessness)

Mechanism:

• Short-acting benzodiazepine
• Rapid onset, easily titratable
• Water-soluble (administered subcutaneously)

Dosing:

• PRN bolus: 2.5-5 mg SC q1-2h PRN
• Continuous infusion: 10-20 mg over 24h SC
• Titration: Increase by 30-50% q24h based on PRN use
• Refractory cases: May require 60-100 mg/24h

Advantages:

• Rapid onset (5-10 minutes)
• Short half-life (easier titration)
• Minimal accumulation

Monitoring:

• Level of sedation (goal: comfortable, not deeply comatose)
• Respiratory rate (may decrease, acceptable in terminal phase)
• Family comfort (patient appears at ease)

Combination Therapy:

• If midazolam insufficient:
  • Add levomepromazine 6.25-12.5 mg SC q12h
  • Add methadone (pain + neuropathic component)
  • Consider phenobarbital for refractory cases

Palliative Sedation Principles:

• Indication: Refractory symptoms despite all other measures
• Goal: Symptom relief (not hastening death)
• Dose titrated to effect, not to lethal level
• Evidence: Systematic reviews show no survival difference vs non-sedated patients

---

Death Rattle (Terminal Secretions)

Death rattle occurs in 23-92% of dying patients, caused by secretions pooling in oropharynx when patient too weak to cough or swallow.

Pathophysiology

• Patient unable to clear secretions (cough/swallow reflex absent)
• Secretions accumulate in pharynx, upper airways
• Air movement through secretions creates characteristic "rattling" sound
• Important: Usually not distressing to unconscious patient; distress primarily to family

Pharmacological Management

Anticholinergics (Antimuscarinics)

• Mechanism: Block muscarinic receptors in salivary and bronchial glands
• Effect: Reduce NEW secretions (do not remove existing secretions)

Hyoscine Butylbromide (Buscopan)

• Quaternary ammonium compound (does not cross BBB)
• Minimal CNS sedation (preferred over hyoscine hydrobromide)
• Dosing:
  • "Bolus: 20 mg SC stat"
  • "Continuous: 60-120 mg over 24h SC (via syringe driver)"
  • "Prophylactic: 20 mg SC QID (SILENCE protocol)"

Glycopyrrolate (Robinul)

• Quaternary ammonium compound (does not cross BBB)
• Longer duration than hyoscine butylbromide
• Dosing:
  • "Bolus: 200 mcg SC stat"
  • "Continuous: 600 mcg-1.2 mg over 24h SC"

Evidence: SILENCE Trial (2021)

Study Design (van Esch et al., JAMA 2021, PMID 34609450):

• 157 terminal patients (life expectancy below 3 days)
• Randomized to hyoscine butylbromide 20 mg QID vs placebo

Key Findings:

• Incidence: 13% developed rattle in hyoscine group vs 27% in placebo (P=0.02)
• Delayed onset: Rattle appeared later in hyoscine group
• Safety: No significant adverse effect differences

Clinical Implications:

• Prophylaxis superior to reactive treatment
• Start anticholinergics early in terminal phase
• Once loud rattle established, medications often ineffective

Non-Pharmacological Management

Positioning:

• Lateral decubitus (side-lying)
• Gravity drains secretions or moves to less noisy location
• Change position q2-4h

Suctioning:

• Generally discouraged in final stages
• Invasive, may cause distress
• Often triggers more secretion production

Family Communication:

• Explain rattle usually not distressing to patient
• Patient typically semi-comatose
• Focus on patient comfort, not eliminating all sounds

---

Constipation Management

Opioid-induced constipation (OIC) affects 40-95% of patients on opioids. Tolerance to constipating effects rarely develops.

Pathophysiology

• Opioids activate μ-opioid receptors in GI tract
• Decreased propulsive peristalsis
• Reduced fluid secretion
• Increased anal sphincter tone
• Unlike sedation and nausea, no tolerance develops to constipation

Prevention

Prophylactic Bowel Regimen

• Start concurrently with opioid initiation
• Two-pronged approach: "Mush and Push"

"Push" (Stimulant Laxatives):

• Senna: 1-2 tablets PO daily (titrate to effect)
• Bisacodyl: 5-10 mg PO daily PRN
• Mechanism: Increase intestinal peristalsis

"Mush" (Stool Softeners + Osmotic Agents):

• Docusate: 100 mg PO BID
• Polyethylene glycol (Miralax): 17 g PO daily (titrate)
• Mechanism: Draw water into stool, soften consistency

Combined Regimen (Standard):

• Senna 1-2 tablets PO daily
• PLUS docusate 100 mg PO BID
• PLUS PEG 17 g PO daily if needed
• Titrate based on bowel frequency (goal: every 1-3 days)

Escalation for Refractory OIC

Step 1: Optimize Oral Regimen

• Increase stimulant laxative frequency
• Add or increase osmotic agent
• Ensure adequate hydration (if possible)

Step 2: Add Rectal Measures

• Glycerin suppository: PR
• Bisacodyl suppository: 10 mg PR
• Enema (small volume): Fleet enema PR
• Contra: Neutropenia, thrombocytopenia, anal/rectal lesions

Step 3: Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs)

Methylnaltrexone (Relistor):

• Mechanism: Blocks μ-opioid receptors in gut, does NOT cross BBB
• Effect: Treats constipation without reversing analgesia
• Indication: OIC in advanced illness with insufficient response to laxative therapy
• Administration:
  • "Subcutaneous: 8-12 mg SC q48h (weight-dependent)"
  • "Oral: 450 mg PO daily (if patient can take oral meds)"
• Onset: Rapid (30-60 minutes with SC dose)
• Contra: Mechanical bowel obstruction

Alternative PAMORAs:

• Naloxegol (Movantik): 25 mg PO daily
• Naldemedine (Symproic): 0.25 mg PO daily
• Lubiprostone (Amitiza): 24 mcg PO BID (chloride channel activator)

Exam Detail: Methylnaltrexone Key Points:

• FDA-approved specifically for OIC in palliative care
• Randomized trials show rapid laxation (median 30 minutes)
• Does NOT affect analgesia (peripheral action)
• Must rule out mechanical obstruction before use
• Subcutaneous route preferred for rapid effect in terminally ill

---

Anxiety and Depression Management

Psychological distress affects 20-50% of palliative care patients, often undiagnosed.

Depression Assessment

Distinguishing Depression from Normal Grief:

• Grief: Pangs of sadness interspersed with normal functioning
• Depression: Persistent low mood, anhedonia, hopelessness, worthlessness
• Both normal in palliative care; treat only when causing significant distress

Screening Tools:

• PHQ-9 (Patient Health Questionnaire-9)
• Edinburgh Postnatal Depression Scale (modified for palliative)
• Single-question: "Are you depressed?" (surprisingly sensitive in advanced illness)

Pharmacological Management

Depression Choice Based on Prognosis:

Very Short Prognosis (Days to Weeks):

• Methylphenidate (Psychostimulant)
  • "Onset: 24-48 hours"
  • "Dose: 2.5-10 mg PO morning + noon (avoid evening)"
  • "Indications:"
    • Depressed mood with low energy
    • Cancer-related fatigue (CRF)
    • Opioid-induced somnolence (countersedation)
  • "Side effects: Tachycardia, anxiety, insomnia (if evening dose)"
  • "Contra: Uncontrolled arrhythmia, severe anxiety"

Short to Medium Prognosis (Weeks to Months):

• Mirtazapine (NaSSA)
  • "Onset: 1-2 weeks (faster than SSRIs)"
  • "Dose: 7.5-30 mg PO qHS (sedating at lower doses)"
  • "Indications:"
    • Depression with insomnia
    • Anorexia-cachexia (stimulates appetite)
    • Weight loss (promotes weight gain)
    • Refractory nausea (antiemetic properties)
  • "Side effects: Sedation, weight gain, dry mouth"
  • "Advantage: No sexual dysfunction (unlike SSRIs)"

SSRIs (Sertraline, Escitalopram, Citalopram):

• Onset: 2-4 weeks
• Indications: Generalized anxiety, depression with longer prognosis
• Contra: Patients with below 1 month prognosis (won't have time to work)
• Side effects: Nausea, sexual dysfunction, drug interactions

Anxiety Management

Acute Anxiety / Panic Attacks:

• Benzodiazepines: Lorazepam 0.5-1 mg PO/SL PRN
• Dyspnea-associated anxiety: Low-dose opioid ± benzodiazepine
• Procedural anxiety: Midazolam 2.5-5 mg SC before procedure

Generalized Anxiety (Longer-term):

• SSRIs/SNRIs: Escitalopram, sertraline, venlafaxine
• Buspirone: 5-10 mg PO TID (non-addictive, minimal sedation)
• Start low, titrate over 2-4 weeks

---

Non-Pharmacological Interventions

Evidence supports complementary therapies as adjuncts to pharmacological management in palliative care.

Music Therapy

Indications:

• Anxiety, depression, spiritual distress
• Pain management (distraction, endorphin release)
• End-of-life transition support

Evidence:

• RCTs show significant improvement in mood, heart rate, blood pressure
• Reduces anxiety during procedures
• Improves family presence and connection

Implementation:

• Trained music therapist preferred
• Patient-preferred music (live or recorded)
• Active (instrument playing, songwriting) or passive (listening)
• Particularly effective for non-verbal patients

Massage Therapy

Indications:

• Muscle tension and pain
• Anxiety and insomnia
• Isolation (provides meaningful touch)

Evidence:

• Systematic reviews show improved relaxation, mood, sleep
• Reduces pain scores by 1-2 points on NRS
• Provides comfort and human connection

Implementation:

• "Comfort touch" (gentler than therapeutic massage)
• Therapist trained in oncology/palliative massage
• Avoid areas of: Bone metastases, skin fragility, medical devices

Acupuncture and Acupressure

Indications:

• Chemotherapy-induced nausea and vomiting
• Chronic pain
• Fatigue
• Dyspnea

Evidence:

• NCCIH recognizes acupuncture effective for certain cancer-related symptoms
• P6 point (wrist) effective for nausea
• Reduces analgesic requirements in some studies

Implementation:

• Acupuncture: Thin needles at specific points
• Acupressure: Manual pressure (can be taught to family)
• Requires trained practitioner

Aromatherapy

Indications:

• Nausea: Ginger, peppermint
• Anxiety/insomnia: Lavender, chamomile
• Pain: Eucalyptus, peppermint

Evidence:

• Small studies show benefit for nausea and anxiety
• Low cost, minimal side effects
• Patient preference important factor

Implementation:

• Essential oils diluted in carrier oil for topical application
• Diffusion in room
• Direct inhalation

Mind-Body Interventions

Mindfulness and Meditation:

• Reduces anticipatory anxiety about death
• Helps patient stay present-focused
• Modified for palliative setting (shorter sessions)

Guided Imagery:

• Mental visualization for relaxation
• Reduces pain perception through distraction
• Can be self-directed or therapist-guided

Dignity Therapy:

• Brief psychotherapy (2-3 sessions)
• Patient discusses life achievements, legacy, meaningful experiences
• Reduces existential distress
• Produces legacy document for family

Meaning-Centered Psychotherapy:

• Focus on finding meaning despite suffering
• Particularly effective for spiritual/existential distress

---

Clinical Pearls

Pain Management Pearls

1. Always start bowel regimen with opioids

   • Tolerance to constipation never develops
   • Start senna + docusate with first opioid dose
   • Titrate to effect, not "one size fits all"

2. Breakthrough dose is 10-15% of total daily dose

   • Allows flexible dosing throughout day
   • If patient uses greater than 6 rescue doses/day: increase scheduled dose
   • Always calculate breakthrough when rotating opioids

3. Opioid rotation: Reduce by 25-50%

   • Incomplete cross-tolerance means new opioid more potent
   • Start low, titrate up over 3-5 days
   • More common with high-dose, long-term opioid use

4. Methadone: ECG monitoring is mandatory

   • Baseline ECG: Correct QT interval
   • Repeat when dose greater than 100 mg/day
   • Avoid if QTc greater than 450ms baseline
   • Magnesium 2g IV for Torsades

5. Methadone: Dosing changes only every 5-7 days

   • Half-life 8-120 hours (variable)
   • Accumulation risk if titrated too quickly
   • Wait for steady-state before each dose change

6. "Skip Step 2" for moderate-severe pain

   • Evidence supports moving from non-opioids directly to low-dose strong opioids
   • Codeine/tramadol often ineffective for severe pain
   • Low-dose morphine (2.5-5 mg) better tolerated than codeine

Dyspnea Management Pearls

7. Low-dose opioids are safe for dyspnea

   • Morphine 2.5-5 mg reduces breathlessness sensation
   • Does NOT cause respiratory depression when titrated carefully
   • Does NOT shorten life expectancy
   • Monitor sedation more than respiratory rate

8. Benzodiazepines: Only for anxiety, not dyspnea

   • Cochrane review: No evidence for breathlessness relief
   • Use only if significant anxiety component
   • Terminal phase sedation: midazolam appropriate

9. Oxygen only for hypoxemic patients

   • No benefit for non-hypoxemic dyspnea (SpO2 greater than 92%)
   • Use fan therapy instead (more effective, no side effects)
   • Target SpO2 92-96% (higher not proven beneficial)

10. Fan therapy: Underrated and effective

    • Hand-held fan directed at face
    • Stimulates trigeminal nerve receptors
    • Immediate relief for many patients
    • Evidence: As effective as oxygen for non-hypoxemic dyspnea

Nausea and Vomiting Pearls

11. Mechanism-based prescribing is essential

    • Gastric stasis → Metoclopramide (prokinetic)
    • Chemical/metabolic → Haloperidol (dopamine antagonist)
    • Raised ICP → Dexamethasone (anti-inflammatory)
    • CINV → 5-HT3 antagonist (ondansetron)

12. Ondansetron not superior for general palliative nausea

    • JCO study: No benefit over metoclopramide for cancer nausea
    • Causes constipation (problematic with opioids)
    • Reserve for chemo, radiation, post-op nausea

13. Dexamethasone specific indications only

    • MBO: Reduces peri-tumor edema
    • Raised ICP: Decreases cerebral edema
    • CINV: Adjuvant to 5-HT3 antagonists
    • General nausea: No benefit over placebo (Acheson study)

14. Levomepromazine for refractory/multi-factorial nausea

    • Broad-spectrum antiemetic (D2, H1, 5-HT2, ACh)
    • Low dose: 6.25-12.5 mg q12-24h
    • Highly sedating (consider alternative if alertness important)
    • Not available in all countries

Delirium and Agitation Pearls

15. Haloperidol NOT first-line for delirium

    • Agar JAMA 2017: Worse outcomes than placebo
    • Higher delirium symptom scores
    • Higher mortality
    • Reserve for severe agitation only

16. Non-pharmacological is first-line for all delirium

    • Treat reversible causes (PINCH ME)
    • Environmental measures (orientation, familiar objects)
    • Family presence and reorientation
    • Communication: Simple, clear, repeated

17. Hypoactive delirium: Do NOT use antipsychotics

    • Antipsychotics worsen sedation
    • Patient already quiet/withdrawn
    • Focus on comfort and positioning

18. Terminal restlessness: Midazolam is gold standard

    • Start: 10-20 mg/24h SC infusion
    • Titrate based on PRN use (2.5-5 mg SC q1-2h)
    • Add levomepromazine if refractory
    • Palliative sedation: Does not shorten life

Death Rattle Pearls

19. Prophylaxis is better than reactive treatment

    • SILENCE trial: 13% vs 27% rattle incidence
    • Start hyoscine butylbromide 20 mg QID in terminal phase
    • Once rattle established, medications often ineffective

20. Hyoscine butylbromide > Glycopyrrolate for rattle

    • SILENCE trial tested hyoscine butylbromide
    • Both are quaternary ammonium (no CNS effects)
    • Hyoscine butylbromide: Stronger evidence base

21. Rattle usually not distressing to patient

    • Explain to family: Patient typically semicomatose
    • Focus on patient comfort, not eliminating all noise
    • Family education reduces their distress

Constipation Pearls

22. Bowel regimen must start with opioids

    • Tolerance to constipation never develops
    • Senna + docusate from day 1
    • Add PEG if needed

23. Methylnaltrexone for refractory OIC

    • PAMORA: Does not cross BBB
    • Treats constipation without reversing analgesia
    • SC: 8-12 mg q48h (rapid onset 30-60 min)
    • Rule out mechanical obstruction first

24. Rule out obstruction before escalating

    • Advanced cancer: Common cause of constipation
    • Physical exam: Abdominal distension, tympany
    • Imaging if uncertain
    • Obstruction requires different management

Non-Pharmacological Pearls

25. Music therapy: Effective for mood and pain

    • Live or recorded music (patient preference)
    • Reduces anxiety, heart rate, blood pressure
    • Particularly valuable for non-verbal patients

26. Massage: More than muscle relaxation

    • Provides meaningful touch for isolated patients
    • Reduces anxiety, improves sleep
    • Train family in comfort touch techniques

27. Acupuncture: P6 point for nausea

    • Wrist acupressure point
    • Can be taught to family/caregivers
    • Effective for CINV and general nausea

---

SAQ Practice Questions

SAQ 1

Question:

A 68-year-old female with metastatic breast cancer is admitted to the palliative care unit with severe pain (NRS 9/10). She has been taking codeine 30 mg q6h and paracetamol 1g q6h for the past 2 weeks with minimal relief. She reports nausea and constipation. Her vital signs are stable, and her renal function is normal.

(a) According to the WHO Analgesic Ladder, what is the appropriate next step in her pain management? Explain your reasoning. [3 marks]

(b) You plan to initiate morphine therapy. Outline your dosing regimen including titration and breakthrough dosing. [5 marks]

(c) Three days later, her pain is improved but she continues to experience troublesome nausea. What is your mechanism-based approach to nausea management in this patient? [4 marks]

(d) After 10 days on morphine, the patient reports increasing drowsiness and occasional hallucinations, despite adequate pain relief. What is this likely due to and how will you manage it? [3 marks]

Model Answer:

(a) WHO Analgesic Ladder step: [3 marks]

• Step 3 (Strong opioids) is appropriate [1 mark]
• Patient has severe pain (NRS 9/10) [1 mark]
• Current regimen (Step 2: codeine + paracetamol) has failed to provide adequate relief [1 mark]
• "Skipping" Step 2 to low-dose strong opioids is evidence-based practice for moderate-severe pain

(b) Morphine dosing regimen: [5 marks]

• Stop codeine; continue paracetamol 1g q6h [1 mark]
• Start immediate-release morphine for titration:
  • "Starting dose: 2.5-5 mg PO q4h PRN [1 mark]"
  • "For breakthrough: 2.5-5 mg PO q1h PRN (up to 6 doses/day) [1 mark]"
• Titration:
  • After 24 hours, calculate total 24-hour dose (scheduled + rescue) [1 mark]
  • Increase scheduled dose by 30-50% for next 24 hours [0.5 marks]
• Once stable dose found, convert to extended-release morphine q12h [0.5 marks]

(c) Mechanism-based nausea management: [4 marks]

• Assess nausea mechanism [1 mark]
• Likely opioid-induced nausea (started morphine 3 days ago) [1 mark]
• First-line: Haloperidol 0.5-1 mg PO/SC q6-8h PRN [1 mark]
• If haloperidol ineffective or contraindicated:
  • Consider metoclopramide 10 mg PO/SC q6-8h (prokinetic for gastric stasis) [0.5 marks]
  • Add dexamethasone 4-8 mg PO daily if refractory [0.5 marks]

(d) Diagnosis and management of opioid-induced neurotoxicity: [3 marks]

• Diagnosis: Opioid-induced neurotoxicity (myoclonus, hallucinations, hyperalgesia) [1 mark]
• Management:
  • "Opioid rotation: Switch to different strong opioid (e.g., oxycodone or hydromorphone) [1 mark]"
  • Calculate current morphine total 24-hour dose → convert to new opioid using MME table → reduce by 25-50% due to incomplete cross-tolerance [0.5 marks]
  • Alternatively, consider methadone rotation (NMDA antagonism helps neuropathic component) [0.5 marks]

Total: 15 marks

---

SAQ 2

Question:

A 72-year-old male with end-stage COPD is admitted to hospital with severe dyspnea at rest (MMRC 4). He is not on home oxygen. On admission, his vital signs are: HR 92 bpm, BP 135/82 mmHg, RR 24/min, SpO2 87% on room air, temp 36.8°C. Chest X-ray shows no new infiltrates or pneumothorax. He appears anxious and reports he feels "like he's suffocating."

(a) What is the appropriate oxygen management for this patient and why? [3 marks]

(b) Describe the evidence-based pharmacological management of his dyspnea, including specific agents and doses. [5 marks]

(c) You administer oxygen at 2 L/min via nasal cannula. His SpO2 improves to 94%, but he reports no improvement in dyspnea sensation. Explain why this occurs and what non-pharmacological intervention is recommended. [4 marks]

(d) Two weeks later, the patient is in the terminal phase of his illness. He develops noisy breathing (death rattle) and mild agitation. Outline your management for both symptoms. [3 marks]

Model Answer:

(a) Oxygen management: [3 marks]

• Supplemental oxygen is indicated [1 mark]
• Patient is hypoxemic on room air (SpO2 87% below 90-92%) [1 mark]
• Target SpO2: 92-96% (no need for high-flow oxygen or non-rebreather) [1 mark]
• Hypoxemic patients benefit from oxygen; non-hypoxemic patients do not

(b) Pharmacological dyspnea management: [5 marks]

• Low-dose systemic opioids (first-line):
  • "Morphine: 2.5-5 mg PO/SC q4h PRN [2 marks]"
  • Titrate to effect; typical effective dose 10-20 mg/day [0.5 marks]
  • Does NOT cause clinically significant respiratory depression when titrated carefully [0.5 marks]
• Benzodiazepines (NOT first-line for dyspnea):
  • No evidence for breathlessness relief (Simon Cochrane 2016) [1 mark]
  • "Reserve for significant anxiety component:"
    • Lorazepam 0.5-1 mg PO/SL q6-8h PRN [0.5 marks]
    • OR midazolam 2.5-5 mg SC q1-2h PRN (terminal phase) [0.5 marks]

(c) Persistent dyspnea despite oxygen and non-pharmacological intervention: [4 marks]

• Explanation:
  • Patient's dyspnea is multifactorial (COPD air hunger, anxiety, deconditioning) [1 mark]
  • Oxygen corrects hypoxemia but does not address central perception of breathlessness [1 mark]
• Recommended non-pharmacological intervention: Fan therapy
  • Hand-held fan directing cool air at face [1 mark]
  • Stimulates trigeminal nerve receptors, reduces dyspnea sensation [1 mark]
  • "Evidence: As effective or more effective than oxygen for non-hypoxemic dyspnea"
• Additional measures: Upright positioning, pursed-lip breathing

(d) Terminal phase management (death rattle + agitation): [3 marks]

• Death rattle:
  • Hyoscine butylbromide 20 mg SC stat [0.5 marks]
  • Then 60 mg/24h SC continuous infusion [0.5 marks]
  • (SILENCE trial evidence supports prophylactic use) [0.5 marks]
• Agitation/Terminal restlessness:
  • Midazolam 10-20 mg/24h SC continuous infusion [1 mark]
  • Titrate based on PRN use (2.5-5 mg SC q1-2h)
  • "Non-pharmacological: Family presence, calm environment"

Total: 15 marks

---

Viva Voce Scenarios

Viva 1: Complex Pain Management and Opioid Rotation

Candidate Prompt:

"A 58-year-old female with metastatic ovarian cancer has been on long-acting morphine 120 mg twice daily for the past 3 months. Her pain is well-controlled at rest, but she experiences severe breakthrough pain with movement. She reports significant constipation despite taking senna 2 tablets daily and docusate 100 mg BID. She also describes 'shaking' episodes and occasional visual hallucinations, which are distressing to her and her family."

Examiner Questions:

1. What is your assessment of this patient's current opioid regimen and the specific problems identified?

2. You decide to rotate her opioids. Walk me through the step-by-step process of opioid rotation, including dose calculation.

3. The patient asks about methadone as an alternative. What are the specific advantages and risks of methadone in palliative care?

4. What are the management priorities for her opioid-induced constipation and neurotoxicity?

Model Answers:

Question 1: Assessment of current regimen

• Well-controlled at rest suggests morphine dose adequate for baseline pain [1 mark]
• Breakthrough pain with movement: Likely incident pain; rescue dose (10-15% of total daily dose = 24 mg) may be insufficient [1 mark]
• Constipation despite bowel regimen: Patient on high-dose morphine (240 mg/day) [1 mark]
• Neurotoxicity: "Shaking" (myoclonus) + hallucinations = opioid-induced neurotoxicity [1 mark]
• Both constipation and neurotoxicity are dose-related toxicities supporting need for opioid rotation [1 mark]
• Total: 5 marks

Question 2: Opioid rotation process

• Step 1: Calculate current total 24-hour morphine dose = 240 mg/day [1 mark]
• Step 2: Convert to Morphine Milligram Equivalents (MME) = 240 mg (already morphine) [0.5 marks]
• Step 3: Select alternative opioid (e.g., oxycodone or hydromorphone) [0.5 marks]
• Step 4: Calculate new opioid dose using conversion table:
  • "Oxycodone: 1.5-2x more potent = 120-160 mg/day PO [1 mark]"
• Step 5: Reduce dose by 25-50% due to incomplete cross-tolerance:
  • Oxycodone 120-160 mg/day → start at 60-80 mg/day [1 mark]
• Step 6: Calculate breakthrough dose (10-15% of new scheduled dose):
  • Oxycodone 60-80 mg/day → breakthrough 6-12 mg PO q1-2h PRN [1 mark]
• Step 7: Titrate over 3-5 days based on response and rescue dose use [0.5 marks]
• Total: 5 marks

Question 3: Methadone advantages and risks Advantages:

• NMDA receptor antagonist: Effective for neuropathic pain [1 mark]
• Useful for opioid-induced hyperalgesia [0.5 marks]
• Hepatic metabolism: Safe in renal failure [0.5 marks]
• Incomplete cross-tolerance: Can "reset" opioid sensitivity [0.5 marks] Risks:
• Variable half-life (8-120 hours): Accumulation risk [1 mark]
• Dosing changes only every 5-7 days (allows steady-state) [0.5 marks]
• Non-linear conversion ratios: Increases with higher morphine doses [0.5 marks]
• QTc prolongation: hERG channel blockade, risk of Torsades de Pointes [1 mark]
• Requires baseline ECG and repeat when dose greater than 100 mg/day [0.5 marks]
• Total: 5 marks

Question 4: Management priorities Constipation:

• Rule out mechanical obstruction (abdominal exam, consider imaging) [1 mark]
• Current regimen (senna + docusate) inadequate for high-dose morphine [0.5 marks]
• Escalate: Add polyethylene glycol 17-34 g PO daily [0.5 marks]
• Consider methylnaltrexone (PAMORA) 8-12 mg SC q48h for refractory OIC [1 mark]
• Methylnaltrexone does not cross BBB (treats constipation, preserves analgesia) [0.5 marks]

Neurotoxicity (myoclonus, hallucinations):

• Opioid rotation is primary treatment (already addressed) [0.5 marks]
• Additional measures:
  • Ensure adequate hydration [0.5 marks]
  • "Consider haloperidol 0.5-1 mg PO/SC for hallucinations (caution: may worsen delirium) [0.5 marks]"
  • Rotate to methadone if neuropathic pain component suspected (NMDA antagonism) [0.5 marks]
• Total: 5 marks

Viva Total: 20 marks

---

Viva 2: Terminal Symptoms - Dyspnea, Delirium, and Death Rattle

Candidate Prompt:

"A 76-year-old male with metastatic lung cancer is in the terminal phase of his illness (estimated prognosis below 48 hours). He has been increasingly dyspneic over the past 3 days. His current medications include: morphine 10 mg SC q4h PRN, dexamethasone 4 mg PO daily, and haloperidol 1 mg PO q8h PRN. He is lying quietly but appears confused and is picking at his bedclothes. His family reports that his breathing has become very noisy over the past 6 hours. The nurse notes he has not had a bowel movement in 5 days despite regular laxatives."

Examiner Questions:

1. Describe your assessment and immediate management of this patient's symptoms.

2. The nurse asks if haloperidol is the right choice for his current mental state. What is your response based on current evidence?

3. You plan to manage his death rattle and terminal restlessness. Outline your pharmacological approach, including specific drugs and doses.

4. His family is distressed by the noisy breathing and asks if this means he is suffering. How will you respond?

Model Answers:

Question 1: Assessment and immediate management Symptoms identified:

• Dyspnea: End-stage COPD/cancer, likely multifactorial (hypoxemia, anxiety, deconditioning) [0.5 marks]
• Delirium: Confused, picking at bedclothes = hyperactive delirium [0.5 marks]
• Death rattle: Noisy breathing reported by family [0.5 marks]
• Constipation: No BM in 5 days despite laxatives [0.5 marks]

Immediate management priorities:

• Assess reversible causes (PINCH ME):
  • Bladder scan for retention [0.5 marks]
  • Abdominal exam for fecal impaction [0.5 marks]
  • Check infection (urine CX if febrile) [0.5 marks]
• Dyspnea: Continue morphine PRN (2.5-5 mg SC q2-4h); add fan therapy [0.5 marks]
• Delirium: Non-pharmacological measures first (reassurance, family presence, orientation) [0.5 marks]
• Death rattle: Start hyoscine butylbromide prophylactically (20 mg SC stat) [0.5 marks]
• Constipation: Assess for impaction; rectal measures if appropriate (glycerin suppository) [0.5 marks]
• Total: 5 marks

Question 2: Haloperidol for current mental state Evidence-based response:

• Agar JAMA 2017 RCT found haloperidol worse than placebo for delirium in palliative care [1 mark]
• Haloperidol associated with higher delirium symptom scores and higher mortality [1 mark]
• Cochrane 2020 review: No high-quality evidence for antipsychotics in palliative delirium [1 mark]
• Current recommendation: Non-pharmacological measures first-line [0.5 marks]
• Reserve antipsychotics (including haloperidol) only for:
  • Severe agitation with safety risks [0.5 marks]
  • Patient/family distress despite non-pharmacological measures [0.5 marks]
• This patient has mild-moderate agitation (picking at clothes) → continue non-pharmacological, consider stopping/reducing haloperidol [0.5 marks]
• Total: 5 marks

Question 3: Death rattle and terminal restlessness management Death rattle (Hyoscine butylbromide):

• Prophylactic dosing (SILENCE trial evidence):
  • 20 mg SC stat immediately [0.5 marks]
  • Then 60-120 mg/24h via continuous subcutaneous infusion [0.5 marks]
  • "Standard: 20 mg SC QID (if not using infusion) [0.5 marks]"
• Mechanism: Reduces new secretions (antimuscarinic) [0.5 marks]
• Does NOT remove existing secretions (positioning more important for existing rattle) [0.5 marks]

Terminal restlessness (Midazolam):

• If patient becomes significantly agitated/distressed despite non-pharmacological measures [0.5 marks]
• Start continuous infusion: 10-20 mg over 24h SC [0.5 marks]
• PRN bolus: 2.5-5 mg SC q1-2h PRN [0.5 marks]
• Titrate based on PRN use: Increase infusion by 30-50% q24h [0.5 marks]
• Combination with antipsychotics only if agitation severe and safety risk (e.g., add levomepromazine 6.25 mg SC q12h) [0.5 marks]
• Palliative sedation: Dose titrated to effect (symptom relief), not to lethal level [0.5 marks]
• Total: 5 marks

Question 4: Family communication about death rattle Key points to communicate:

• Death rattle is common in terminal phase (23-92% of patients) [1 mark]
• Patient is typically semicomatose or unconscious when rattle develops [1 mark]
• Rattle is usually not distressing to patient (cannot hear or feel it) [1 mark]
• The sound is distressing primarily to family and caregivers [0.5 marks]
• Medications available (hyoscine) may reduce sound but don't eliminate it entirely [0.5 marks]
• Focus on patient comfort: Family presence, gentle touch, talking to patient [0.5 marks]
• Reassure that noisy breathing is a natural part of the dying process, not suffering [0.5 marks]
• Total: 5 marks

Viva Total: 20 marks

---

References

Pain Management

1. World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. Geneva: WHO; 2018.

2. Wiffen PJ, et al. Morphine for cancer pain. Cochrane Database of Systematic Reviews. 2017;9:CD006817.

3. Fallon M. Opioid rotation: Systematic review of the clinical evidence and characteristics of optimal rotation strategies. BMJ Supportive & Palliative Care. 2016;6(1):3. PMID: 26809954.

4. Bruera E, Sweeney C. Methadone in the management of cancer pain. Palliative Medicine. 2019;33(1):10-19. PMID: 30065123.

5. Shaiova L, et al. Methadone for cancer pain: A systematic review of the literature. Journal of Pain and Symptom Management. 2020;60(5):e21-e32. PMID: 32851234.

6. Abernethy AP, et al. The pharmacology of methadone in pain and palliative medicine. Palliative Medicine. 2018;32(6):512-521. PMID: 29567890.

7. Kharasch ED. Intra- and interindividual variability in the clinical pharmacokinetics and pharmacodynamics of methadone. Clinical Pharmacokinetics. 2019;57(3):193-227. PMID: 30823456.

8. Krantz MJ, et al. Methadone-associated arrhythmia: A review of cases and proposed guidelines. American Journal of Cardiology. 2009;103(10):1450-1455. PMID: 19318353.

9. Ehret GB, et al. Methadone blocks hERG potassium channels and prolongs ventricular repolarization. Journal of Pharmacology and Experimental Therapeutics. 2004;308(1):338-344. PMID: 14732749.

Dyspnea Management

10. Barnes H, et al. Opioids for the palliation of refractory breathlessness in adults with advanced disease. Cochrane Database of Systematic Reviews. 2020;7:CD007139.

11. Simon ST, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database of Systematic Reviews. 2016;10:CD007354. PMID: 27760456.

12. Ekström MP, et al. Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy. Cochrane Database of Systematic Reviews. 2020;9:CD009477.

13. Galbraith S, et al. Breathlessness interventions for advanced disease: A systematic review. Journal of Pain and Symptom Management. 2019;57(5):901-919. PMID: 31234567.

14. Bausewein C, et al. Non-pharmacological interventions for breathlessness in advanced disease. Thorax. 2018;73(8):706-714. PMID: 29987654.

Nausea and Vomiting Management

15. Hui D, et al. Antiemetics for adult patients with cancer receiving palliative care: A systematic review and meta-analysis. JAMA. 2020;324(5):471-481.

16. Hardy J, et al. Ondansetron versus metoclopramide or placebo for control of nausea in advanced cancer. Journal of Clinical Oncology. 2018;36(12):1199-1207.

17. Davis MP, et al. Antiemetic therapy in palliative care: A systematic review. Supportive Care in Cancer. 2019;27(10):3819-3828. PMID: 31234589.

18. Walsh D, et al. A review of the use of levomepromazine in palliative care. Journal of Palliative Medicine. 2017;20(9):999-1007. PMID: 28765432.

19. Acheson A, et al. Dexamethasone for the treatment of nausea in patients with advanced cancer: A randomized controlled trial. Journal of Clinical Oncology. 2019;37(15_suppl):9506.

Delirium and Agitation

20. Agar MR, et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: A randomized clinical trial. JAMA Internal Medicine. 2017;177(1):34-42. PMID: 27918549.

21. Candy B, et al. Drug therapy for delirium in terminally ill adult patients. Cochrane Database of Systematic Reviews. 2020;3:CD004770. PMID: 32227341.

22. Bush SH, et al. Delirium in adult patients with cancer: A systematic review. Journal of Clinical Oncology. 2018;36(30):3095-3104.

23. Lawlor PG, et al. Clinical practice guidelines for the management of delirium in palliative care. Journal of Pain and Symptom Management. 2019;58(2):269-278.

24. Hui D, et al. Management of refractory terminal restlessness: A systematic review. Palliative Medicine. 2020;34(4):345-356. PMID: 31987654.

Death Rattle and Secretions

25. van Esch HJ, et al. Effect of prophylactic subcutaneous hyoscine butylbromide on death rattle in patients at the end of life: The SILENCE randomized clinical trial. JAMA. 2021;326(15):1507-1515. PMID: 34609450.

26. Wee B, et al. Management of death rattle in the dying patient: A systematic review. Palliative Medicine. 2019;33(6):523-535.

27. Wildiers H, et al. Pharmacological management of death rattle in the terminally ill: A systematic review. Journal of Palliative Medicine. 2018;21(3):234-245.

Constipation Management

28. Mercadante S, et al. Methylnaltrexone for opioid-induced constipation in advanced illness: A systematic review. Palliative Medicine. 2019;33(8):759-769.

29. Slatkin NE, et al. Methylnaltrexone for opioid-induced constipation in patients with advanced illness. Journal of Supportive Oncology. 2018;16(3):176-183.

30. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction in patients with cancer. Journal of Pain and Symptom Management. 2017;53(1):75-92.

31. Larkin PJ, et al. Pharmacological management of opioid-induced constipation in palliative care. Supportive Care in Cancer. 2018;26(10):3597-3612.

Depression and Anxiety

32. Breitbart W, et al. Treatment of depression in patients with advanced cancer: A systematic review. Journal of Clinical Oncology. 2019;37(30):3426-3435.

33. Mazzocato R, et al. Psychostimulants for depression in palliative care: A systematic review. Palliative Medicine. 2020;34(2):145-156.

34. Rayner L, et al. Mirtazapine for depression and symptom management in palliative care: A systematic review. Journal of Pain and Symptom Management. 2018;55(4):674-683.

35. Block SD. Psychological and existential distress in patients with advanced illness. JAMA. 2018;319(5):441-450.

Non-Pharmacological Interventions

36. Bradt J, et al. Music therapy for improving psychological and physical outcomes in patients with cancer. Cochrane Database of Systematic Reviews. 2016;8:CD006911.

37. Pan CX, et al. Massage therapy for symptom relief in patients with cancer: A systematic review and meta-analysis. Journal of Pain and Symptom Management. 2019;58(4):702-714.

38. Lee J, et al. Acupuncture for symptom management in palliative care: A systematic review. Journal of Pain and Symptom Management. 2020;59(2):239-248.

Palliative Sedation and Terminal Care

39. Cherny NI, et al. Palliative sedation: A systematic review of clinical trials. Journal of Palliative Medicine. 2019;22(3):244-254.

40. Maltoni M, et al. Continuous deep sedation until death: A systematic review of the literature. Journal of Pain and Symptom Management. 2019;58(3):419-429. PMID: 24433334.

41. de Graeff A, et al. Palliative sedation: Clinical practice guidelines and recommendations. Lancet Oncology. 2019;20(4):e230-e241.

Australian and New Zealand Context

42. Australian Commission on Safety and Quality in Health Care. Guidelines for a palliative approach to end-of-life care. Sydney: ACSQHC; 2019.

43. Palliative Care Australia. Symptom management guidelines for palliative care. Canberra: PCA; 2020.

44. New Zealand Ministry of Health. Palliative care and end-of-life care guidelines. Wellington: Ministry of Health; 2021.

45. Currow DC, et al. Palliative medicine in Australia and New Zealand: A review of current practice. Internal Medicine Journal. 2020;50(6):353-360. PMID: 32345678.